BridgeMD
A multicentre randomised study on percutaneous stellate ganglion block as first-line treatment in patients with electrical storm: the STAR 2 study
EU CTIS ID: 2024-520387-34-00
What this study is testing
The primary objective of the STAR 2 study is to assess if the efficacy of PSGB, expressed as the number of patients with complete suppression of treated VA (with ATP, internal DC shock or external DC shock) during the first three hours after treatment, is superior to amiodarone, considered the standard of care.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age≥ 18 years
- More than 3 episodes of fast-VT/VF treated by the internal or external defibrillator in the 12 hours before randomization and at least one in the three hours before.
- Fast-VT or FV requiring internal or external treatment
- Any structural heart disease
- Acute or choric coronary disease
- CPVT
You likely can't join if
- Brugada syndrome or early repolarization syndrome
- Known allergy or hypersensitivity or previous idiosyncrasy to amiodarone, lidocaine, bupivacaine or to other anesthetics allowed in the study
- Other contraindications to amiodarone administration (e.g. QT prolongation, LQT syndrome, severe bradycardia, second or third degree atrio-ventricular block)
- Neck judged unfeasible for the procedure by the clinicians
- Previous heart transplantation
- Previous surgical sympathetic denervation
See the full eligibility criteria
- Age≥ 18 years
- More than 3 episodes of fast-VT/VF treated by the internal or external defibrillator in the 12 hours before randomization and at least one in the three hours before.
- Fast-VT or FV requiring internal or external treatment
- Any structural heart disease
- Acute or choric coronary disease
- CPVT
- Brugada syndrome or early repolarization syndrome
- Known allergy or hypersensitivity or previous idiosyncrasy to amiodarone, lidocaine, bupivacaine or to other anesthetics allowed in the study
- Other contraindications to amiodarone administration (e.g. QT prolongation, LQT syndrome, severe bradycardia, second or third degree atrio-ventricular block)
- Neck judged unfeasible for the procedure by the clinicians
- Previous heart transplantation
- Previous surgical sympathetic denervation
- Previous ablation of the stellate ganglion block
- Ongoing treatment with intravenous AAD drugs. Enrolment may be possible under certain circumstances (see Table 3 page 62-63) in case of recurrences after discontinuation
- Refractory cardiac arrest
- Active enrollment in another pharmacological study
- Pregnancy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.